On January 24, 2024, CardioNavi MedTech (Wuhan) Co., Ltd., a member company of Grand Pharmaceutical Group Limited (Grand Pharma), officially opened its Shanghai R&D Center. This represents the fulfillment of Grand Pharma’s development strategy of “independent research and development + global expansion”, as well as our determination to expand the product pipeline by continuously exploring high-quality innovative projects globally to enhance our comprehensive strength and vigorously transform into an innovative and internationalized company.

CardioNavi MedTech (Wuhan) Co., Ltd. Shanghai R&D Center will serve the research and development of mitral valve replacement products in the field of structural heart devices, marking the company’s determination to expand into structural heart disease products.

The R&D center is equipped with a flow dynamics-fatigue testing area, a mechanical performance testing area, a valve treatment and chemical testing area, and imported equipment such as a stent laser cutter, a valve laser cutter, a valve accelerated fatigue testing machine, a steady-state flow performance testing machine, and a pulsatile flow performance testing machine.

Shanghai R&D Center is located in Wisdom Plaza, Pujiang Town, Minhang District, Shanghai. It is the third international R&D center under the field of cerebro-cardiovascular precision interventional diagnosis and treatment, with “international technology, service for China” as the core of the strategy, following the R&D center in Wuhan Optics Valley and Changzhou.